Abstract
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of aggressive non-Hodgkin lymphoma and despite recent chemotherapeutic advances up to half of all patients relapse. We conducted a phase two trial: oral lenalidomide in combination with rituximab is active in elderly patients with relapsed/refractory DLBCL with a high percentage of patients achieving a continuous CR after lenalidomide maintenance. Background: Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of aggressive non-Hodgkin lymphoma and despite recent chemotherapeutic advances up to half of all patients relapse. Here we report the results from a phase 2, single-arm, single-center trial evaluating the safety and efficacy of lenalidomide plus rituximab in elderly patients with relapsed or refractory DLBCL. Patients and Methods: Between March and June 2009, elderly patients (65 years of age or older) with relapsed/refractory DLBCL who had been heavily pretreated were recruited. Oral lenalidomide (20 mg/d for 21 days of each 28-day cycle) was initiated for four cycles and rituximab (375 mg/m 2) was administered on day 1 and day 21 of each 28-day cycle for four cycles. After this induction phase, patients achieving a complete response (CR), partial response (PR), or stable disease (SD) were given lenalidomide maintenance therapy at the same schedule for another 8 months. Results: A total of 23 patients with a median of three prior treatments (range, 2 to 8) were included. The overall response rate (CR + PR) at the end of the induction phase was 35% (n = 8). Ten patients (7 CR, 1 PR, and 2 SD patients) were eligible for lenalidomide maintenance and 8 of these patients achieved a CR. Adverse events were manageable and the most common included neutropenia and thrombocytopenia. Conclusion: Oral lenalidomide in combination with rituximab is active in elderly patients with relapsed/refractory DLBCL with a high percentage of patients achieving a continuous CR after lenalidomide maintenance.
| Original language | English |
|---|---|
| Pages (from-to) | 462-466 |
| Number of pages | 5 |
| Journal | Clinical Lymphoma, Myeloma and Leukemia |
| Volume | 11 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - Dec 2011 |
Fingerprint
Keywords
- Diffuse large B-cell lymphoma
- Elderly patients
- Lenalidomide
- Relapsed/refractory
- Rituximab
ASJC Scopus subject areas
- Cancer Research
- Hematology
- Oncology
Cite this
Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma : A phase 2 trial. / Zinzani, Pier Luigi; Pellegrini, Cinzia; Gandolfi, Letizia; Stefoni, Vittorio; Quirini, Federica; Derenzini, Enrico; Broccoli, Alessandro; Argnani, Lisa; Pileri, Stefano; Baccarani, Michele.
In: Clinical Lymphoma, Myeloma and Leukemia, Vol. 11, No. 6, 12.2011, p. 462-466.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma
T2 - A phase 2 trial
AU - Zinzani, Pier Luigi
AU - Pellegrini, Cinzia
AU - Gandolfi, Letizia
AU - Stefoni, Vittorio
AU - Quirini, Federica
AU - Derenzini, Enrico
AU - Broccoli, Alessandro
AU - Argnani, Lisa
AU - Pileri, Stefano
AU - Baccarani, Michele
PY - 2011/12
Y1 - 2011/12
N2 - Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of aggressive non-Hodgkin lymphoma and despite recent chemotherapeutic advances up to half of all patients relapse. We conducted a phase two trial: oral lenalidomide in combination with rituximab is active in elderly patients with relapsed/refractory DLBCL with a high percentage of patients achieving a continuous CR after lenalidomide maintenance. Background: Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of aggressive non-Hodgkin lymphoma and despite recent chemotherapeutic advances up to half of all patients relapse. Here we report the results from a phase 2, single-arm, single-center trial evaluating the safety and efficacy of lenalidomide plus rituximab in elderly patients with relapsed or refractory DLBCL. Patients and Methods: Between March and June 2009, elderly patients (65 years of age or older) with relapsed/refractory DLBCL who had been heavily pretreated were recruited. Oral lenalidomide (20 mg/d for 21 days of each 28-day cycle) was initiated for four cycles and rituximab (375 mg/m 2) was administered on day 1 and day 21 of each 28-day cycle for four cycles. After this induction phase, patients achieving a complete response (CR), partial response (PR), or stable disease (SD) were given lenalidomide maintenance therapy at the same schedule for another 8 months. Results: A total of 23 patients with a median of three prior treatments (range, 2 to 8) were included. The overall response rate (CR + PR) at the end of the induction phase was 35% (n = 8). Ten patients (7 CR, 1 PR, and 2 SD patients) were eligible for lenalidomide maintenance and 8 of these patients achieved a CR. Adverse events were manageable and the most common included neutropenia and thrombocytopenia. Conclusion: Oral lenalidomide in combination with rituximab is active in elderly patients with relapsed/refractory DLBCL with a high percentage of patients achieving a continuous CR after lenalidomide maintenance.
AB - Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of aggressive non-Hodgkin lymphoma and despite recent chemotherapeutic advances up to half of all patients relapse. We conducted a phase two trial: oral lenalidomide in combination with rituximab is active in elderly patients with relapsed/refractory DLBCL with a high percentage of patients achieving a continuous CR after lenalidomide maintenance. Background: Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of aggressive non-Hodgkin lymphoma and despite recent chemotherapeutic advances up to half of all patients relapse. Here we report the results from a phase 2, single-arm, single-center trial evaluating the safety and efficacy of lenalidomide plus rituximab in elderly patients with relapsed or refractory DLBCL. Patients and Methods: Between March and June 2009, elderly patients (65 years of age or older) with relapsed/refractory DLBCL who had been heavily pretreated were recruited. Oral lenalidomide (20 mg/d for 21 days of each 28-day cycle) was initiated for four cycles and rituximab (375 mg/m 2) was administered on day 1 and day 21 of each 28-day cycle for four cycles. After this induction phase, patients achieving a complete response (CR), partial response (PR), or stable disease (SD) were given lenalidomide maintenance therapy at the same schedule for another 8 months. Results: A total of 23 patients with a median of three prior treatments (range, 2 to 8) were included. The overall response rate (CR + PR) at the end of the induction phase was 35% (n = 8). Ten patients (7 CR, 1 PR, and 2 SD patients) were eligible for lenalidomide maintenance and 8 of these patients achieved a CR. Adverse events were manageable and the most common included neutropenia and thrombocytopenia. Conclusion: Oral lenalidomide in combination with rituximab is active in elderly patients with relapsed/refractory DLBCL with a high percentage of patients achieving a continuous CR after lenalidomide maintenance.
KW - Diffuse large B-cell lymphoma
KW - Elderly patients
KW - Lenalidomide
KW - Relapsed/refractory
KW - Rituximab
UR - http://www.scopus.com/inward/record.url?scp=84857654592&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84857654592&partnerID=8YFLogxK
U2 - 10.1016/j.clml.2011.02.001
DO - 10.1016/j.clml.2011.02.001
M3 - Article
C2 - 21859554
AN - SCOPUS:84857654592
VL - 11
SP - 462
EP - 466
JO - Clinical Lymphoma, Myeloma and Leukemia
JF - Clinical Lymphoma, Myeloma and Leukemia
SN - 2152-2669
IS - 6
ER -